Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (91-100 of 179) with videos related to

Pageof 18
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2019
Treatment of brain metastases of castration-resistant prostate cancer with <sup>225</sup>Ac-PSMA-617Mike M Sathekge, Frank Bruchertseifer, Ismaheel O Lawal, et al.
Expert Review of Anticancer Therapy|August 27, 2014
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNARuth A Bryan, Zewei Jiang, Thomas Jandl, et al.
Molecular Therapy. Oncology|February 24, 2026
EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancerGábor Bakos, Ulrike Bauder-Wüst, Jonathan Landry, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 27, 2007
Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiationStéphane Supiot, Francois Thillays, Emmanuel Rio, et al.
Cancer Biology & Therapy|June 22, 2007
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancerEmma Y Song, Syed M Abbas Rizvi, Chang F Qu, et al.
Frontiers in Medicine|November 6, 2015
Alpha Particles Induce Autophagy in Multiple Myeloma CellsJean-Baptiste Gorin, Sébastien Gouard, Jérémie Ménager, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2018
<sup>225</sup>Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot studyMike Sathekge, Frank Bruchertseifer, Otto Knoesen, et al.
Nuclear Medicine and Biology|October 1, 2011
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer modelAnna M E Gustafsson, Tom Bäck, Jörgen Elgqvist, et al.
Seminars in Nuclear Medicine|March 17, 2020
<sup>225</sup>Ac- and <sup>213</sup>Bi-Substance P Analogues for Glioma TherapyLeszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, et al.
EJNMMI Research|February 11, 2026
Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancerMariam Amghar, Tobias Rausch, Hilal Özgür, et al.
Pageof 18

Showing results (91-100 of 179) with videos related to

Sort By:
Pageof 18
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2019
Treatment of brain metastases of castration-resistant prostate cancer with <sup>225</sup>Ac-PSMA-617Mike M Sathekge, Frank Bruchertseifer, Ismaheel O Lawal, et al.
Expert Review of Anticancer Therapy|August 27, 2014
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNARuth A Bryan, Zewei Jiang, Thomas Jandl, et al.
Molecular Therapy. Oncology|February 24, 2026
EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancerGábor Bakos, Ulrike Bauder-Wüst, Jonathan Landry, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 27, 2007
Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiationStéphane Supiot, Francois Thillays, Emmanuel Rio, et al.
Cancer Biology & Therapy|June 22, 2007
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancerEmma Y Song, Syed M Abbas Rizvi, Chang F Qu, et al.
Frontiers in Medicine|November 6, 2015
Alpha Particles Induce Autophagy in Multiple Myeloma CellsJean-Baptiste Gorin, Sébastien Gouard, Jérémie Ménager, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2018
<sup>225</sup>Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot studyMike Sathekge, Frank Bruchertseifer, Otto Knoesen, et al.
Nuclear Medicine and Biology|October 1, 2011
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer modelAnna M E Gustafsson, Tom Bäck, Jörgen Elgqvist, et al.
Seminars in Nuclear Medicine|March 17, 2020
<sup>225</sup>Ac- and <sup>213</sup>Bi-Substance P Analogues for Glioma TherapyLeszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, et al.
EJNMMI Research|February 11, 2026
Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancerMariam Amghar, Tobias Rausch, Hilal Özgür, et al.
Pageof 18